Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Current Assets (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Current Assets for 7 consecutive years, with $871.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Assets rose 70.74% to $871.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $871.2 million, a 70.74% increase, with the full-year FY2025 number at $871.2 million, up 70.74% from a year prior.
  • Current Assets was $871.2 million for Q4 2025 at Kymera Therapeutics, up from $528.3 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $871.2 million in Q4 2025 to a low of $340.8 million in Q1 2021.
  • A 5-year average of $489.8 million and a median of $472.6 million in 2021 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: surged 82.85% in 2021, then decreased 23.95% in 2023.
  • Kymera Therapeutics' Current Assets stood at $451.3 million in 2021, then dropped by 7.06% to $419.4 million in 2022, then dropped by 3.36% to $405.3 million in 2023, then grew by 25.89% to $510.3 million in 2024, then surged by 70.74% to $871.2 million in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Current Assets are $871.2 million (Q4 2025), $528.3 million (Q3 2025), and $728.3 million (Q2 2025).